This phase 3 trial is comparing the effectiveness of using either two targeted therapies (pembrolizumab and olaparib), or one targeted therapy (pembrolizumab) with a chemotherapy (pemetrexed) for the treatment of metastatic Non-Small-Cell Lung Cancer.
This trial is treating patients with Non-Small-Cell Lung Cancer.
This is a systemic therapy.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer
There will be two parts of this trial. The first part is the Induction phase. All patients eligible to participate in this trial will receive intravenous administration of Pembrolizumab, Pemetrexed and a platinum based chemotherapy during the Induction phase. The intravenous infusion will occur over four 21 day cycles on Day 1. Following Induction phase, the Maintenance phase will commence. People eligible to participate in the Maintenance phase will either receive intravenous administration of Pembrolizumab on Day 1 of each 21 day cycle and orally administered Olaparib twice daily, or Pembrolizumab and Pemetrexed both administered through intravenous infusion on Day 1 of each 21 day cycle. Maintenance will continue for up to 31 cycles.
Recruiting Hospitals Read More